These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 14624812)
21. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Russell V; de Villiers A; Sagvolden T; Lamm M; Taljaard J Brain Res; 1995 Apr; 676(2):343-51. PubMed ID: 7614004 [TBL] [Abstract][Full Text] [Related]
22. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats. Ruocco LA; Carnevale UA; Treno C; Sadile AG; Melisi D; Arra C; Ibba M; Schirru C; Carboni E Behav Brain Res; 2010 Jun; 210(1):99-106. PubMed ID: 20156489 [TBL] [Abstract][Full Text] [Related]
23. The dopaminergic system in attention deficit/hyperactivity disorder. Ohno M Congenit Anom (Kyoto); 2003 Jun; 43(2):114-22. PubMed ID: 12893970 [TBL] [Abstract][Full Text] [Related]
24. What the rodent prefrontal cortex can teach us about attention-deficit/hyperactivity disorder: the critical role of early developmental events on prefrontal function. Sullivan RM; Brake WG Behav Brain Res; 2003 Nov; 146(1-2):43-55. PubMed ID: 14643458 [TBL] [Abstract][Full Text] [Related]
25. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder. Viggiano D; Ruocco LA; Arcieri S; Sadile AG Neural Plast; 2004; 11(1-2):133-49. PubMed ID: 15303310 [TBL] [Abstract][Full Text] [Related]
26. Atypical prefrontal connectivity in attention-deficit/hyperactivity disorder: pathway to disease or pathological end point? Liston C; Malter Cohen M; Teslovich T; Levenson D; Casey BJ Biol Psychiatry; 2011 Jun; 69(12):1168-77. PubMed ID: 21546000 [TBL] [Abstract][Full Text] [Related]
27. Downregulation of Dopamine D1-like Receptor Pathways of GABAergic Interneurons in the Anterior Cingulate Cortex of Spontaneously Hypertensive Rats. Satoh H; Suzuki H; Saitow F Neuroscience; 2018 Dec; 394():267-285. PubMed ID: 30394321 [TBL] [Abstract][Full Text] [Related]
28. Rodent models of attention-deficit/hyperactivity disorder. Sagvolden T; Russell VA; Aase H; Johansen EB; Farshbaf M Biol Psychiatry; 2005 Jun; 57(11):1239-47. PubMed ID: 15949994 [TBL] [Abstract][Full Text] [Related]
29. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Carlsson ML Prog Neuropsychopharmacol Biol Psychiatry; 2001 Jan; 25(1):5-26. PubMed ID: 11263758 [TBL] [Abstract][Full Text] [Related]
30. GABA(A) receptors in the ventral tegmental area control bidirectional reward signalling between dopaminergic and non-dopaminergic neural motivational systems. Laviolette SR; van der Kooy D Eur J Neurosci; 2001 Mar; 13(5):1009-15. PubMed ID: 11264674 [TBL] [Abstract][Full Text] [Related]
32. Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder--the spontaneously hypertensive rat. Russell VA; de Villiers AS; Sagvolden T; Lamm MC; Taljaard JJ Brain Res Bull; 2000 Sep; 53(2):187-92. PubMed ID: 11044595 [TBL] [Abstract][Full Text] [Related]
33. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder]. Castellanos FX; Acosta MT Rev Neurol; 2011 Mar; 52 Suppl 1():S155-60. PubMed ID: 21365598 [TBL] [Abstract][Full Text] [Related]
34. Striatal dynamics as determinants of reduced gambling vulnerability in the NHE rat model of ADHD. Oggiano M; Zoratto F; Palombelli G; Festucci F; Laviola G; Curcio G; Canese R; Adriani W Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109886. PubMed ID: 32045636 [TBL] [Abstract][Full Text] [Related]
36. Intranasal application of dopamine reduces activity and improves attention in Naples High Excitability rats that feature the mesocortical variant of ADHD. Ruocco LA; de Souza Silva MA; Topic B; Mattern C; Huston JP; Sadile AG Eur Neuropsychopharmacol; 2009 Oct; 19(10):693-701. PubMed ID: 19328660 [TBL] [Abstract][Full Text] [Related]
37. Catecholamines in ADHD: a postscript. Pliszka SR; McCracken JT J Am Acad Child Adolesc Psychiatry; 1997 Jul; 36(7):869-70. PubMed ID: 9204662 [No Abstract] [Full Text] [Related]
38. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Frank MJ; Santamaria A; O'Reilly RC; Willcutt E Neuropsychopharmacology; 2007 Jul; 32(7):1583-99. PubMed ID: 17164816 [TBL] [Abstract][Full Text] [Related]
39. Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Oakley NR; Hayes AG; Sheehan MJ Psychopharmacology (Berl); 1991; 105(2):204-8. PubMed ID: 1686655 [TBL] [Abstract][Full Text] [Related]
40. Unexpected global impact of VTA dopamine neuron activation as measured by opto-fMRI. Lohani S; Poplawsky AJ; Kim SG; Moghaddam B Mol Psychiatry; 2017 Apr; 22(4):585-594. PubMed ID: 27457809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]